# Prostate Cancer Treatment and Research

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/prostate-cancer-treatment-and-research/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers represents a comprehensive exploration of advancements in prostate cancer research, covering topics such as androgen receptor signaling, genomic profiling, hormone therapy, immunotherapy, genetic mutations, clinical trials, biomarkers, and molecular biology. The papers discuss the molecular determinants of resistance to antiandrogen therapy, the impact of translocations and gene fusions on cancer causation, and the development of second-generation antiandrogens for the treatment of advanced prostate cancer. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10543 |
| Works | 414 |

## Topic papers all

Showing 15 of 414.

- [Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer](https://scholariq.org/papers/docetaxel-plus-prednisone-or-mitoxantrone-plus-prednisone-for-advanced-prostate/)
- [Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy](https://scholariq.org/papers/increased-survival-with-enzalutamide-in-prostate-cancer-after-chemotherapy/)
- [Abiraterone and Increased Survival in Metastatic Prostate Cancer](https://scholariq.org/papers/abiraterone-and-increased-survival-in-metastatic-prostate-cancer/)
- [Screening and Prostate-Cancer Mortality in a Randomized European Study](https://scholariq.org/papers/screening-and-prostate-cancer-mortality-in-a-randomized-european-study/)
- [Integrative Genomic Profiling of Human Prostate Cancer](https://scholariq.org/papers/integrative-genomic-profiling-of-human-prostate-cancer/)
- [Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer](https://scholariq.org/papers/docetaxel-and-estramustine-compared-with-mitoxantrone-and-prednisone-for/)
- [Integrative Clinical Genomics of Advanced Prostate Cancer](https://scholariq.org/papers/integrative-clinical-genomics-of-advanced-prostate-cancer/)
- [Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial](https://scholariq.org/papers/prednisone-plus-cabazitaxel-or-mitoxantrone-for-metastatic-castration-resistant/)
- [The Molecular Taxonomy of Primary Prostate Cancer](https://scholariq.org/papers/the-molecular-taxonomy-of-primary-prostate-cancer/)
- [MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis](https://scholariq.org/papers/mri-targeted-or-standard-biopsy-for-prostate-cancer-diagnosis/)
- [Enzalutamide in Metastatic Prostate Cancer before Chemotherapy](https://scholariq.org/papers/enzalutamide-in-metastatic-prostate-cancer-before-chemotherapy/)
- [Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer](https://scholariq.org/papers/chemohormonal-therapy-in-metastatic-hormone-sensitive-prostate-cancer/)
- [Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy](https://scholariq.org/papers/abiraterone-in-metastatic-prostate-cancer-without-previous-chemotherapy/)
- [Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference](https://scholariq.org/papers/defining-biochemical-failure-following-radiotherapy-with-or-without-hormonal/)
- [Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/lutetium-177-psma-617-for-metastatic-castration-resistant-prostate-cancer/)

## Topic primary papers

Showing 15 of 188.

- [Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer](https://scholariq.org/papers/docetaxel-plus-prednisone-or-mitoxantrone-plus-prednisone-for-advanced-prostate/)
- [Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy](https://scholariq.org/papers/increased-survival-with-enzalutamide-in-prostate-cancer-after-chemotherapy/)
- [Abiraterone and Increased Survival in Metastatic Prostate Cancer](https://scholariq.org/papers/abiraterone-and-increased-survival-in-metastatic-prostate-cancer/)
- [Integrative Genomic Profiling of Human Prostate Cancer](https://scholariq.org/papers/integrative-genomic-profiling-of-human-prostate-cancer/)
- [Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer](https://scholariq.org/papers/docetaxel-and-estramustine-compared-with-mitoxantrone-and-prednisone-for/)
- [Integrative Clinical Genomics of Advanced Prostate Cancer](https://scholariq.org/papers/integrative-clinical-genomics-of-advanced-prostate-cancer/)
- [Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial](https://scholariq.org/papers/prednisone-plus-cabazitaxel-or-mitoxantrone-for-metastatic-castration-resistant/)
- [The Molecular Taxonomy of Primary Prostate Cancer](https://scholariq.org/papers/the-molecular-taxonomy-of-primary-prostate-cancer/)
- [Enzalutamide in Metastatic Prostate Cancer before Chemotherapy](https://scholariq.org/papers/enzalutamide-in-metastatic-prostate-cancer-before-chemotherapy/)
- [Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer](https://scholariq.org/papers/chemohormonal-therapy-in-metastatic-hormone-sensitive-prostate-cancer/)
- [Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy](https://scholariq.org/papers/abiraterone-in-metastatic-prostate-cancer-without-previous-chemotherapy/)
- [Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/lutetium-177-psma-617-for-metastatic-castration-resistant-prostate-cancer/)
- [AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer](https://scholariq.org/papers/ar-v7-and-resistance-to-enzalutamide-and-abiraterone-in-prostate-cancer/)
- [Olaparib for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/olaparib-for-metastatic-castration-resistant-prostate-cancer/)
- [Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer](https://scholariq.org/papers/abiraterone-plus-prednisone-in-metastatic-castration-sensitive-prostate-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.